|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.14 CNY | +0.26% |
|
-1.43% | +0.46% |
| 25-10-27 | Tasly Pharmaceutical's Q3 Profit Rises 17%, Revenue Slips 3%; Shares Down 1% | MT |
| 25-10-24 | Tasly pharmaceutical group Q3 net profit up 16.6% Y/Y | RE |
| Capitalization | 22.62B 3.25B 2.77B 2.57B 2.41B 4.49B 296B 4.82B 29.62B 11.7B 141B 12.19B 11.94B 513B | P/E ratio 2025 * |
19x | P/E ratio 2026 * | 15.9x |
|---|---|---|---|---|---|
| Enterprise value | 19.67B 2.83B 2.41B 2.23B 2.1B 3.91B 257B 4.19B 25.76B 10.18B 122B 10.6B 10.38B 446B | EV / Sales 2025 * |
2.24x | EV / Sales 2026 * | 2.18x |
| Free-Float |
49.28% | Yield 2025 * |
4.72% | Yield 2026 * | 4.8% |
| 1 day | +0.26% | ||
| 1 week | -1.43% | ||
| Current month | +0.46% | ||
| 1 month | -0.59% | ||
| 3 months | -4.78% | ||
| 6 months | -6.54% | ||
| Current year | +0.46% |
| 1 week | 14.95 |  | 15.36 |
| 1 month | 14.95 | | 15.49 |
| Current year | 14.95 | | 15.49 |
| 1 year | 14.13 | | 17.69 |
| 3 years | 11.45 | | 18 |
| 5 years | 9.2 | | 18 |
| 10 years | 9.2 | | 34.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jin Yong Cai
CEO | Chief Executive Officer | 54 | 2024-05-07 |
Jie Wei
DFI | Director of Finance/CFO | 49 | 2018-07-08 |
Ying Zhao
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Meng Jiang
BRD | Director/Board Member | 62 | 2007-08-16 |
Ai Jian Wang
BRD | Director/Board Member | 72 | 2021-06-01 |
Jin Yong Cai
BRD | Director/Board Member | 54 | 2006-03-24 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.26% | -1.43% | +4.78% | +30.18% | 3.24B | |
| +0.22% | -3.27% | -15.50% | -33.27% | 6.16B | |
| +1.65% | +0.69% | -17.98% | +13.19% | 4.52B | |
| +0.35% | -1.55% | +50.41% | +43.76% | 4.39B | |
| +2.03% | +1.97% | +15.40% | -37.27% | 4.26B | |
| +1.59% | +3.11% | -3.96% | -8.23% | 3.5B | |
| +0.77% | +1.50% | +9.63% | -20.11% | 2.55B | |
| -0.61% | -2.10% | +14.10% | +1.97% | 2B | |
| +1.39% | +0.05% | -2.44% | +52.08% | 1.69B | |
| +3.18% | +3.49% | +14.83% | +53.11% | 1.69B | |
| Average | +1.08% | +1.01% | +6.93% | +9.54% | 3.4B | |
| Weighted average by Cap. | +1.00% | +0.82% | +5.45% | +2.56% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 8.77B 1.26B 1.07B 995M 936M 1.74B 115B 1.87B 11.48B 4.54B 54.51B 4.72B 4.63B 199B | 9.37B 1.35B 1.15B 1.06B 1B 1.86B 123B 2B 12.27B 4.85B 58.27B 5.05B 4.95B 213B |
| Net income | 1.2B 172M 146M 136M 128M 237M 15.63B 255M 1.57B 619M 7.43B 644M 631M 27.13B | 1.42B 204M 174M 161M 151M 282M 18.55B 302M 1.86B 734M 8.82B 764M 748M 32.18B |
| Net Debt | -2.95B -424M -361M -335M -315M -586M -38.59B -629M -3.86B -1.53B -18.35B -1.59B -1.56B -66.96B | -2.2B -316M -270M -250M -235M -437M -28.79B -469M -2.88B -1.14B -13.69B -1.19B -1.16B -49.97B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-20 | 15.14 ¥ | +0.26% | 7,032,640 |
| 26-01-19 | 15.10 ¥ | +0.33% | 6,218,493 |
| 26-01-16 | 15.05 ¥ | -1.31% | 12,961,870 |
| 26-01-15 | 15.25 ¥ | -0.46% | 7,980,045 |
| 26-01-14 | 15.32 ¥ | -0.26% | 18,069,160 |
End-of-day quote Shanghai S.E., January 19, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600535 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition